C4 Therapeutics, Inc. — Director's Dealing 2023

Sep 20, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2023-09-18

Reporting Person: Boyle Scott N (Chief Business Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-09-18	Stock Option (Right to Buy)	$2.15	A	120000	Acquired	2033-09-17	Common Stock (120000)	Direct

Footnotes

F1: This option shall vest in full on September 18, 2025, subject to the Reporting Person's continued service on such date.